Onkologische Gemeinschaftspraxis
Welcome,         Profile    Billing    Logout  
 9 Trials 
12 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mohm, Johannes
TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

Recruiting
3
870
Europe
R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance)
Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum
Mantle Cell Lymphoma
05/21
05/26
PREPARE, NCT03013946 / 2016-000399-28: Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy

Recruiting
3
430
Europe
Concomitant coaching
AIO-Studien-gGmbH, Pfizer, Crolll Gmbh
Renal Cell Carcinoma, Metastatic, Renal Cell Cancer, Recurrent
01/24
07/24
ADAPTlate, NCT04565054 / 2019-001488-60: Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC

Recruiting
3
1260
Europe
Abemaciclib 50 MG; 150mg 1-0-1 per os, Verzenios
West German Study Group, Eli Lilly and Company, Genomic Health®, Inc.
Breast Cancer Female
08/26
03/28
INFINITY, NCT04389541: Clinical Research Platform on Decision Making and Clinical Impact of Biomarker-Driven Precision Oncology

Completed
N/A
499
Europe
iOMEDICO AG, Bristol-Myers Squibb, Roche Pharma AG
Advanced Solid Tumors or Hematologic Malignancies
06/23
06/23
DigiNet, NCT05818449: Improvement of Personalized Lung Cancer Care Through Digital Connection and Patient Participation

Active, not recruiting
N/A
850
Europe
DigiNet intervention
University of Cologne, Gemeinsamer Bundesausschuss (G-BA), AOK Rheinland/Hamburg, AOK Nordwest, BARMER, University Hospital, Essen, Charite University, Berlin, Germany, Berlin Institute of Health, Helios Klinikum Emil von Behring, University Hospital Carl Gustav Carus, Deutsche Krebsgesellschaft e.V., Berufsverband der Niedergelassenen Hämatologen und Onkologen in Deutschland e.V., AOK Bundesverband, FOM Hochschule für Oekonomie und Management, University Medicine Greifswald, Technische Universität Dresden
Non-small Cell Lung Cancer Stage IV
03/25
03/25
ITP-Registry, NCT05152238: ITP Registry and Accompanying Biospecimen Collection

Recruiting
N/A
1100
Europe
Jena University Hospital, University Hospital Dresden, Novartis, Swedish Orphan Biovitrum, Grifols Biologicals, LLC, Amgen, argenx
Immune Thrombocytopenia
09/26
04/27
Prange-Krex, Gabriele
TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

Recruiting
3
870
Europe
R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance)
Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum
Mantle Cell Lymphoma
05/21
05/26
ADAPTlate, NCT04565054 / 2019-001488-60: Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC

Recruiting
3
1260
Europe
Abemaciclib 50 MG; 150mg 1-0-1 per os, Verzenios
West German Study Group, Eli Lilly and Company, Genomic Health®, Inc.
Breast Cancer Female
08/26
03/28
Alternative-C, NCT05387616: A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination With Obinutuzumab in Patients With Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden

Active, not recruiting
2
98
Europe
Copanlisib, ALIQOPA™, Obinutuzumab, GAZYVARO®
Ludwig-Maximilians - University of Munich, Roche Pharma AG, Bayer
Follicular Lymphoma
09/23
05/26
NCT04263480: Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia

Recruiting
2
99
Europe
Carfilzomib + Ibrutinib, Ibrutinib
Christian Buske, Amgen, Janssen, LP
Waldenstrom Macroglobulinemia
02/28
02/28
NCT04268277: Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY

Recruiting
N/A
56
Europe
Rituximab, Truxima, Pembrolizumab, Keytruda
University of Ulm, X-act Cologne Clinical Research GmbH, Zentrum für Klinische Studien Ulm, Merck Sharp & Dohme LLC, Celltrion Healthcare Co., LTD
Marginal Zone Lymphoma
04/29
04/29
Breuer, Jochen
ADAPTlate, NCT04565054 / 2019-001488-60: Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC

Recruiting
3
1260
Europe
Abemaciclib 50 MG; 150mg 1-0-1 per os, Verzenios
West German Study Group, Eli Lilly and Company, Genomic Health®, Inc.
Breast Cancer Female
08/26
03/28

Download Options